2917-91-1 Usage
General Description
2,3-epoxy-N,N-diethyl-propylamin, also known as N,N-diethyl-2,3-epoxypropylamine, is a chemical compound with the molecular formula C8H17NO. It is an epoxy amine that is commonly used as a curing or cross-linking agent in epoxy and polyurethane resin systems. It is a clear to pale yellow liquid with a characteristic amine odor and is considered to be a hazardous substance. This chemical is known to cause skin irritation, eye irritation, and may be harmful if inhaled or ingested. It is important to handle and use 2,3-epoxy-N,N-diethyl-propylamin with caution and in accordance with safety regulations.
Check Digit Verification of cas no
The CAS Registry Mumber 2917-91-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,9,1 and 7 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 2917-91:
(6*2)+(5*9)+(4*1)+(3*7)+(2*9)+(1*1)=101
101 % 10 = 1
So 2917-91-1 is a valid CAS Registry Number.
InChI:InChI=1/C7H15NO/c1-3-8(4-2)5-7-6-9-7/h7H,3-6H2,1-2H3
2917-91-1Relevant articles and documents
LE CHLOROALLYLLITHIUM COMME SYNTHON DE CHLOROALLYLATION OU COMME EQUIVALENT DU VINYLCARBENE: SYNTHESE REGIOSELECTIVE D'ALCOOLS γ-ETHYLENIQUES β-CHLORES ET DE VINYL-2 OXETANES A PARTIR D'EPOXYDES
Ongoka, P.,Mauze, B.,Miginiac, L.
, p. 139 - 148 (1985)
Chloroallyllithium reacts regioselectively with various epoxides in a "one-pot" reaction to produce either γ-ethylenic β-chloro alcohols or 2-vinyl oxetanes, depending on the experimental conditions used.
Treatment of excessive osteolysis with indolinone compounds
-
, (2008/06/13)
Compounds of Formula I and Formula II, as described herein, are useful for treating excessive osteolysis, by inhibiting M-CSF mediated osteoclast development. The compounds also are useful for inhibiting phosphorylation of CSF1R, and for treating cancers that express CSF1R.
Treatment of acute myeloid leukemia with indolinone compounds
-
, (2008/06/13)
A method of treating acute myeloid leukemia in patient positive for FLT-3-ITD is described. The treatment is accomplished by administration of a compound of Formula I or II as defined herein.
